...testing women with breast cancer who are candidates for drug treatments targeted to the HER-2 tumor receptor. The drugs are Herceptin ® ( trastuzumab ) and lapatinib. His remarks were presented at a symposium sponsored by Abbott Molecular.

In this article: Breast cancer, Cancer, Amplification, Trastuzumab, Lapatinib, Medical advice, Journal of Clinical Oncology, 5-fluorouracil, and Cyclophosphamide

...clinics, drug treatments and publicity campaigns. In contrast to the rejection of sorafenib, when the anti-breast cancer drug Herceptin first came on the market, the then Health Secretary Patricia Hewitt declared that it would be...

In this article: Cancer, Europe, Department of Health, Breast cancer, Lung cancer, Britain, and Labour Party

...between Mullen 's compensation and Biogen's stock performance. Shares of Biogen , which makes the multiple sclerosis drugs Avonex and Tysabri , are trading in the same range as they were in early 2004. During that time, HealthCor said...

In this article: Biogen, Tysabri, Carl Icahn, Cancer, Multiple sclerosis, and Lumiliximab

...could not recoup their costs for the drug. As a result, treatment for AMD would likely have shifted from Avastin to the drug Lucentis , which has a substantially higher cost. Currently the lower-cost Avastin is the more prevalent...

In this article: Avastin, Best interests, Surgery, Cancer, American Academy of Ophthalmology, Lucentis, and Macular degeneration

...off the medicine, a flare-up would occur," she said. In 2006, Jardon said the Federal Drug Administration approved the drug Remicade for colitis , which allowed Johnson to get off Prednisone. Her last flare-up was in September of that...

In this article: Colitis, Crohn, Prednisone, Remicade, Cedar Falls, Asacol, Blood transfusion, and University of Northern Iowa

...a death sentence. But now with three years of data from more than 60,000 patients worldwide who have taken natalizumab (Tysabri ) under strict monitoring by physicians, a new picture is emerging that shows PML is still very much a...

In this article: Biogen Idec, Natalizumab, Elan, FDA, Multiple sclerosis, Rash, Encephalopathy, and Harvard Medical School

...and apoptosis. Mutated KRAS is permanently activated and hinders anti-EGFR therapies based on monoclonal antibodies ( cetuximab and panitumumab ) or tyrosine kinase inhibitors ( erlotinib and gefitinib ). As KRAS mutations are found in 20-30%...

In this article: KRAS, FMR1, University of California, Davis, California, Amplification, Trademark, Gefitinib, Erlotinib, and Mental retardation

...In 30 Years Article Date: 18 Nov 2009 - 0:00 PST The American Society of Clinical Oncology ( ASCO ) has once again recognized Erbitux ® ( cetuximab ) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by...

In this article: Cetuximab, Cancer, Merck KGaA, Irinotecan, Lung cancer, Head and neck cancer, Squamous cell carcinoma, and EU

* Roche unit submits two applications to U.S. FDA * Avastin plus chemotherapy boosts survival rates-studies Adds detail, background) Swiss drugmaker Roche Holding AG <ROG.VX> said on Tuesday its Genentech unit had submitted two...

In this article: Avastin, Breast cancer, Genentech, Taxane, Capecitabine, and U.S. Food and Drug Administration

...and the global market is estimated at over $6.3 billion. DMARDs , including biologics such as Enbrel ®, Humira ®, Cimzia ®, and Remicade ®, accounted for nearly $5.0 billion of that figure. The global market for RA therapies has been...

In this article: Rheumatoid arthritis, Inflammation, Peptide, American College, National Institutes of Health, Medical advice, Hydroxychloroquine, Cimzia, and Autoimmunity

...Co <MRK.N> is likely to prevail over Johnson & Johnson <JNJ.N> in its battle to retain overseas rights to the blockbuster arthritis drug Remicade. "Personally, I feel good that Merck will be able to keep Remicade ," Hassan said on Thursday at...

In this article: Fred Hassan, Merck, Remicade, Schering-Plough Corp, Johnson & Johnson, Pharmacia, Arthritis, and Pfizer Inc

Ireland 's Elan <ELN.I> and U.S. drugmaker Biogen Idec <BIIB.O> have amended the label of their multiple sclerosis drug Tysabri to reflect the increased risk of contracting a potentially deadly brain infection, Elan said in a statement on...

In this article: Elan, Tysabri, Biogen Idec, Progressive multifocal leukoencephalopathy, Multiple sclerosis, Ireland, and U.S.

...Calif.-based Amgen /quotes/comstock/15*!amgn/quotes/nls/amgn (AMGN 54.00, +1.88, +3.61%) has been seeking to have Prolia, also known as denosumab , approved for two treatment indications: bone loss in post-menopausal women and bone loss...

In this article: Amgen Inc., Food and Drug Administration, Revenue, Cancer, Denosumab, Osteoporosis, Hormone, and Neulasta

It will acquire a number of valuable Schering-Plough drugs. But its overseas rights to blockbuster rheumatoid arthritis drug Remicade and to a newer once-monthly arthritis drug called Simponi remain in dispute. Schering-Plough...

In this article: Schering-Plough Corp, Merck, Remicade, Johnson & Johnson, Wyeth, New York Stock Exchange, Pfizer, Arthritis, and Rheumatoid arthritis

Both agents will remain relegated to second- or later-line biological therapy through 2018, behind both Humira and Remicade. "The continued uptake of Humira will be the greatest contributor to market growth over the next five years," said...

In this article: Humira, Crohn's disease, Remicade, Tnf-alpha, Trademark, Cimzia, Tysabri, and Biogen Idec

The company said on Wednesday U.S. health regulators have requested additional clinical trial data on its experimental osteoporosis drug denosumab for prevention of bone loss in prostate and breast cancer patients. That could mean a...

In this article: Amgen Inc, Cancer, Denosumab, Osteoporosis, FDA, Revenue, Tax, and Wall Street

...and Toni Clarke U.S. health regulators delayed approval of Amgen Inc's <AMGN.O> most important new drug, the osteoporosis medicine denosumab , the biotechnology company said on Monday, sending shares down nearly 2 percent. But,...

In this article: Osteoporosis, Amgen Inc, FDA, Denosumab, Cancer, and Risk management

See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, FDA Approval Amgen Provides Update on Status of Prolia(TM) ( Denosumab ) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration...

In this article: Amgen Inc., FDA, Osteoporosis, Cancer, Denosumab, Hormone, Breast cancer, Rheumatoid arthritis, and World Health Organization